Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Protein Sciences
Meriden, Connecticut, United Statesproteinsciences.com ↗
- Ownership
- Private
- Employees
- ~48
- Development stage
- Other
01
Overview
The company developed Flublok®, the first FDA-approved recombinant influenza vaccine, showing a clinically significant efficacy advantage over traditional egg-based vaccines in adults ≥50 years old. Sanofi acquired the company in August 2017 for $750M to expand its non-egg-based flu vaccine portfolio.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant protein vaccines
- Industry
- Biotech
02
Partnerships
U.S. Biomedical Advanced Research and Development Authority (BARDA)Sinergium Biotecnologia SAOrygen Biotecnologia
Beyond the preview
Go deeper on Protein Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein Sciences.